4-amino-6,7-dichloro-1,4-dihydroquinoxaline-2,3-dione | 153504-95-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: 4-amino-6,7-dichloro-1,4-dihydroquinoxaline-2,3-dione
• 英文别名: 4-amino-6,7-dichloro-1H-quinoxaline-2,3-dione
• CAS: 153504-95-1
• 化学式: C₈H₅Cl₂N₃O₂
• 分子量: 246.053
• InChiKey: JMGOTILWSGCZNA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  15
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  75.4
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  异氰酸苯磺酰酯 、 4-amino-6,7-dichloro-1,4-dihydroquinoxaline-2,3-dione 以 N,N-二甲基甲酰胺 为溶剂， 生成 1-(benzenesulfonyl)-3-(6,7-dichloro-2,3-dioxo-4H-quinoxalin-1-yl)urea
  参考文献：
  名称：

  Lead discovery of quinoxalinediones as an inhibitor of dipeptidyl peptidase-IV (DPP-IV) by high-throughput screening

  摘要：

  N-Ureido-quinoxalinedione derivatives have been discovered as leads for a novel series of dipeptidyl peptidase-IV (DPP-IV) inhibitors through high-throughput screening of our chemical library. A brief structure-activity relationship of the compounds was investigated. Among them, entry 5 showed the most potent inhibitory activity. The nitro group in quinoxaline moiety and the aromatic sulfonyl substituted ureido functional group seem to be important to increase the potency dramatically. (C) 2004 Published by Elsevier Ltd.

  DOI：

  10.1016/j.bmcl.2004.02.065
• 作为产物：
  描述：

  2,3-二羟基-6,7-二氯喹喔啉 在 氢氧化钾 、 potassium carbonate 、 hydroxylamine-O-sulfonic acid 作用下， 生成 4-amino-6,7-dichloro-1,4-dihydroquinoxaline-2,3-dione
  参考文献：
  名称：

  Lead discovery of quinoxalinediones as an inhibitor of dipeptidyl peptidase-IV (DPP-IV) by high-throughput screening

  摘要：

  N-Ureido-quinoxalinedione derivatives have been discovered as leads for a novel series of dipeptidyl peptidase-IV (DPP-IV) inhibitors through high-throughput screening of our chemical library. A brief structure-activity relationship of the compounds was investigated. Among them, entry 5 showed the most potent inhibitory activity. The nitro group in quinoxaline moiety and the aromatic sulfonyl substituted ureido functional group seem to be important to increase the potency dramatically. (C) 2004 Published by Elsevier Ltd.

  DOI：

  10.1016/j.bmcl.2004.02.065

文献信息

• Glycine receptor antagonists and the use thereof
  申请人：The State of Oregon, acting by and through The Oregon State Board of

  公开号：US05514680A1

  公开（公告）日：1996-05-07

  Methods of treating or preventing neuronal loss associated with stroke, ischemia, CNS trauma, hypoglycemia and surgery, as well as treating neurodegenerative diseases including Alzheimer's disease, amyotrophic lateral sclerosis, Huntington's disease and Down's syndrome, treating or preventing the adverse consequences of the hyperactivity of the excitatory amino acids, as well as treating anxiety, chronic pain, convulsions, inducing anesthesia and treating psychosis are disclosed by administering to an animal in need of such treatment a compound having high affinity for the glycine binding site, lacking PCP side effects and which crosses the blood brain barrier of the animal. Also disclosed are novel 1,4-dihydroquinoxaline-2,3-diones, and pharmaceutical compositions thereof. Also disclosed are highly soluble ammonium salts of 1,4-dihydroquinoxaline-2,3-diones.

  治疗或预防与中风、缺血、中枢神经系统创伤、低血糖和手术相关的神经元损失的方法，以及治疗包括阿尔茨海默病、肌萎缩侧索硬化、亨廷顿病和唐氏综合症在内的神经退行性疾病，治疗或预防兴奋性氨基酸过度活跃的副作用，以及治疗焦虑、慢性疼痛、癫痫、诱导麻醉和治疗精神病的方法，通过向需要此类治疗的动物施用一种对甘氨酸结合位点具有高亲和力、无PCP副作用且能穿过动物血脑屏障的化合物来进行披露。还披露了新型的1,4-二氢喹诺酮-2,3-二酮，及其药物组合物。还披露了1,4-二氢喹诺酮-2,3-二酮的高度可溶性铵盐。
• GLYCINE RECEPTOR ANTAGONISTS AND THE USE THEREOF
  申请人：The Regents of the University of California

  公开号：EP0647137B1

  公开（公告）日：2008-08-13
• EP0647137A4
  申请人：——

  公开号：EP0647137A4

  公开（公告）日：1998-09-16
• US5514680A
  申请人：——

  公开号：US5514680A

  公开（公告）日：1996-05-07
• US5622952A
  申请人：——

  公开号：US5622952A

  公开（公告）日：1997-04-22